Efficacy and safety of combined TACE-HAIC and targeted immunotherapy in primary liver cancer with portal vein tumor thrombus

1

The study evaluated the safety and efficacy of TACE-HAIC combined with targeted immunotherapy in patients with HCC and PVTT.
2

A total of 114 patients were analyzed, with 42 in the quadruple-therapy group and 72 in the triple-therapy group.
3

The quadruple-therapy group showed a significantly higher objective response rate for portal vein tumor thrombus compared to the triple-therapy group.
4

No significant differences were observed in overall survival, progression-free survival, or intrahepatic progression-free survival between the two groups.
5

The combination therapy effectively induced regression of intraportal tumor thrombi, supporting its use as a treatment strategy for PVTT.

1